News Releases

Summary Toggle Teligent, Inc. Announces Third Quarter 2018 Results

BUENA, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (the "Company"), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights Total revenue of $18.3

November 13, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces $120 Million Financing Commitment From Ares

BUENA, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced today that the Company secured a financing commitment from funds managed by Ares Management, L.P. (“Ares”) (NYSE: ARES), on November 12, 2018. Pursuant to the commitment, Ares

November 13, 2018

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Third Quarter 2018 Results

BUENA, N.J. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Tuesday November 13 th , 2018 to discuss the 3 rd quarter 2018 financial results and business

November 12, 2018

PDF Version
Summary Toggle Teligent, Inc. to Present at Jefferies London Healthcare Conference on Wednesday November 14, 2018

BUENA, N.J. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies London Healthcare Conference . The Conference is taking place November 14-15, 2018 in London, UK .

November 2, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Desoximetasone Ointment USP 0.05%

BUENA, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

October 24, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Cream USP, 0.05%

BUENA, N.J. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

October 17, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Ointment USP, 0.05%

BUENA, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of

October 2, 2018

PDF Version
Summary Toggle Teligent Secures Critical Supply during Canadian National Drug Crisis despite Worldwide Shortage

TORONTO , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ:TLGT) (“Teligent”), a specialty generic pharmaceutical company, averted a national sterile water and sodium chloride crisis by securing inventory to cover 100% of the Canadian Market following a breakdown in the global supply

August 16, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces Second Quarter 2018 Results

BUENA, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2018 . Second Quarter 2018 Highlights The Company adopted ASC 606: Revenue from

August 8, 2018

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Second Quarter 2018 Results

BUENA, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Wednesday August 8, 2018 to discuss the 2 nd quarter 2018 financial results and business

August 3, 2018

PDF Version